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Adenocarcinomas of the colon and rectum are graded using a two-tiered system into 
histologic low-grade and high-grade tumors based on the proportion of gland formation. The 
current grading system does not apply to subtypes of carcinomas associated with a high 
frequency of microsatellite instability (MSI), such as mucinous and medullary carcinomas. 
We investigated the combined effect of histologic grade and MSI status on survival for 738 
patients with colorectal carcinoma (48% female; mean age at diagnosis 68.2 years). The 
proportion of high-grade adenocarcinoma was 18%. MSI was observed in 59 
adenocarcinomas (9%), with higher frequency in high-grade tumors compared with low-
grade tumors (20% vs. 6%; P<0.001). Using Cox regression models, adjusting for sex, age at 
diagnosis and stratifying by the American Joint Committee on Cancer (AJCC) stage, 
microsatellite stable (MSS) high-grade tumors were associated with increased hazard of all-
cause and colorectal cancer-specific mortality: hazard ratio (HR) 2.09 (95% confidence 
interval (CI), 1.58-2.77) and 2.54 (95% CI, 1.86-3.47), respectively, both P<0.001. A new 
grading system separating adenocarcinoma into low-grade (all histologic low-grade and MSI 
high-grade) and high-grade (MSS histologic high-grade) gave a lower Akaike information 
criterion value when compared with the current grading system and, thus, represented a better 
model fit to stratify patients according to survival. We found that patients with a high-grade 
adenocarcinoma had significantly shorter survival than patients with low-grade 
adenocarcinoma only if the tumor was MSS, suggesting that the grading of colorectal 
adenocarcinoma with high-grade histologic features should be made according to the MSI 
















Most colorectal carcinomas are adenocarcinomas of usual type (adenocarcinoma NOS, not 
otherwise specified). Since the first grading systems were established [1, 2], pathologists 
have routinely included histologic grade in their reports of resected colorectal 
adenocarcinomas. Adenocarcinomas are graded into well-, moderately or poorly 
differentiated tumors (grades 1, 2, 3, respectively) depending on the proportion of gland 
formation in the least differentiated component of the tumor away from the invasive edge, 
according to the World Health Organization (WHO) criteria [3]. Despite low levels of 
agreement among pathologists on this subjective assessment [4, 5], histologic grading has 
been shown to be an independent prognostic factor for colorectal carcinoma [6-9]. This is 
particularly true for the poorly differentiated subgroup that has been most consistently found 
to be associated with adverse clinical outcome. The WHO and the American Joint Committee 
on Cancer (AJCC) recommend a two-tiered histologic grading system: low-grade for well- 
and moderately differentiated adenocarcinomas (50-100% gland formation) and high-grade 
for poorly differentiated adenocarcinomas (0-49% gland formation) [3, 10]. 
 
Testing tumors for microsatellite instability (MSI) by immunohistochemistry for mismatch 
repair (MMR) proteins MLH1, MSH2, PMS2 and MSH6 and/or by molecular-based methods 
is routinely performed for patients diagnosed with colorectal carcinoma, primarily to screen 
for Lynch syndrome. Up to 15% of all colorectal carcinomas demonstrate MSI, more 
frequently secondary to acquired methylation of MLH1 (sporadic cases) than caused by a 
germline mutation in an MMR gene (Lynch syndrome). MSI has been reported to be a strong 
positive prognostic factor by multiple independent studies [11-13]. Some histologic subtypes 
of colorectal carcinomas are more commonly observed in MSI tumors, including medullary 














prognosis associated with the poor differentiation of most of these tumor subtypes contrasts 
with the positive prognosis associated with MSI. Consequently, the current WHO histologic 
grading does not apply to these subtypes of colorectal carcinoma. Additionally, the WHO 
recommends that mucinous carcinomas should be graded according to their MSI status, 
regardless of their morphologic appearance [3]. Such an MSI-based grading principle could 
potentially be applied to colorectal adenocarcinomas of usual type to more effectively stratify 
patients by prognosis. To test this hypothesis, we investigated the survival of a large series of 
patients diagnosed with colorectal adenocarcinoma with respect to histologic grade and MSI 
status.  
 
Patients and Methods 
Study Sample 
Incident colorectal carcinomas were identified from participants enrolled of the Melbourne 
Collaborative Cohort Study (MCCS), a prospective cohort study of 41,514 people (17,045 
males and 24,469 females) recruited between 1990 and 1994 [15].  Participants were aged 27 
to 75 years with almost all aged between the ages 40-69 years at baseline. The study protocol 
was approved by the Cancer Council Victoria’s Human Research Ethics Committee and the 
Human Research Ethics Committee of the Queensland Institute of Medical Research under 
protocol P799. Written informed consent was obtained from all study subjects for the 
investigators to review their medical records.  
 
Data Collection 
Clinical data were collected from medical charts, colonoscopy reports and pathology reports. 
Paraffin-embedded tissue blocks were collected from hospital pathology departments where 














immunohistochemistry and DNA extraction. All surgically resected carcinomas underwent 
standardized review by two pathologists (Jeremy Jass and Christophe Rosty) to assess for a 
set of histologic features including, histologic type (adenocarcinoma, mucinous carcinoma, 
others) and tumor grade. Adenocarcinoma of usual type is defined by a carcinoma of 
intestinal type forming glandular structures with variability in size and configuration, and 
with frequent mucus and cellular debris in the lumen. In poorly differentiated 
adenocarcinomas, gland formations had to be present even if only focally. Following the 
2010 WHO histologic grading system, adenocarcinomas were classified as high-grade if 
<50% gland formation was present in the least differentiated area of the lesion (Figure 1) [3]. 
This area had to be present in at least one microscopic field at magnification x40, away from 
the tumor invading edge. Tumors showing complete absence of differentiation were classified 
as ‘other subtype’, which included undifferentiated carcinoma and medullary carcinoma. The 
diagnosis of medullary carcinoma required sheets of neoplastic cells with typical vesicular 
nuclei and conspicuous tumor infiltrating lymphocytes without any gland formation. If more 
than 50% of the tumor exhibited mucinous differentiation, defined by the presence of pools 
of extracellular mucin containing clusters of carcinomatous cells or individual tumor cells 
including signet ring cells, it was classified as a mucinous carcinoma. Signet ring cell 
carcinoma was defined by the presence of signet ring cells within mucin pools or in a diffuse 
infiltrative pattern occupying >50% of the tumor. Tumors were staged using the AJCC 
criteria [10]. 
 
Immunohistochemical and Molecular Analysis  
Immunohistochemistry was performed on available tissue sections to assess the tumor 
expression of MMR proteins MLH1, PMS2, MSH2 and MSH6 [16]. MSI status was 














deemed MSI if loss of immunohistochemical expression of at least one MMR protein was 
demonstrated and/or ≥30% of MSI markers were unstable. All other tumors were deemed 
microsatellite stable (MSS). 
 
Statistical Analysis  
Statistical analyses were performed with Stata version 11.1 (College Station, TX: StataCorp 
LP).  Time of observation was from the date of diagnosis of the colorectal carcinoma until 
death or March 2013, whichever came first. Kaplan-Meier methods were used to estimate 
separately for overall and disease-specific survival by MSI status (MSI vs. MSS) for all 
histologic types and by histologic grade (low-grade vs. high grade) and MSI status (MSI vs. 
MSS) for the group of adenocarcinoma only. Survival was compared between groups using 
the log-rank test. Cox regression models were used to estimate hazard ratios (HRs) and 
corresponding 95% confidence intervals (CIs) for all-cause mortality and colorectal cancer-
specific mortality associated with histologic grade and MSI status, after adjusting for: sex, 
age at diagnosis (<60, 60-70, >70 years), and stratifying by AJCC stage since hazards were 
non-proportional across stages. The proportional hazards assumption was assessed using 
graphic methods and tests based on Schoenfeld residuals. A two-tailed P value was used for 
all analyses and values less than 0.05 were considered to be statistically significant. We 
calculated the Akaike information criterion (AIC) for each Cox model to assess goodness-of-
fit [18]. The AIC is a method used to measure and compare the relative quality of statistical 
models. AIC takes into account the goodness of fit and the complexity of the model. In this 
context, AIC provides information on the best prognostic model using a set of variables. The 
















We identified 1046 incident carcinomas of the colon or rectum among MCCS participants 
between the study baseline (1990-1994) and 31 December 2009. Histopathologic review was 
undertaken for 795 of the tumors. Complete data for MSI status and histologic grade were 
available for 738 tumors, which were classified as adenocarcinoma of usual type (668 cases, 
91%), mucinous carcinoma (58 cases, 8%), signet ring cell carcinoma (8 cases, 1%), and 
‘other subtype’ including 3 undifferentiated carcinomas and 1 medullary carcinoma (Table 
1).  There were 356 females (48%) and the mean age at diagnosis was 68.2 years (standard 
deviation, 8.2 years). The proportion of high-grade tumors was 18% of adenocarcinomas. 
MSI was observed in 59 adenocarcinomas (9%), with higher frequency in high-grade tumors 
compared with low-grade tumors (20% vs. 6%; P<0.001), in 23 (40%) of mucinous 
carcinomas, in 3 (38%) of signet ring cell carcinomas, in the medullary carcinoma and in 
none of the 3 undifferentiated carcinomas (Table 1).  
 
There were 377 deaths during a median follow-up of 7.5 years (range 2 days to 20.4 years), 
of which 237 (63%) were attributed to colorectal cancer. There was evidence of significantly 
better overall survival and disease-specific survival for MSI tumors, compared with MSS 
tumors of all histologic types (P=0.038 and P=0.0003, respectively) (Figure 2). In the 
subgroup of adenocarcinoma only, there was evidence of significantly lower overall survival 
and disease-specific survival for high-grade MSS tumors, compared with the other three 
tumor groups (MSI low-grade, MSS low-grade, and MSI high-grade) (Figure 3). When 
modeled together, high-grade was associated with an increased hazard for all-cause mortality 
and colorectal cancer-specific mortality: Hazard ratio (HR) 3.02 (95% CI, 2.32-3.92) and 
4.20 (95% CI, 3.13-5.64), respectively, both P<0.001 (Table 2). After adjustment for sex, age 














cause and colorectal cancer-specific mortality: HR 2.09 (95% CI, 1.58-2.77) and 2.54 (95% 
CI, 1.86-3.47), respectively, both P<0.001 (Table 3). 
 
Based on these results, a new grading system that includes MSI status is proposed that 
categorizes adenocarcinomas as low-grade if histologically low-grade (MSS and MSI) or 
high-grade with MSI, and as high-grade if histologically high-grade and MSS (Table 4). The 
AIC values for the adjusted Cox model for all-cause and colorectal cancer-specific mortality 
according to MSI status and histologic grade were 2806.7 and 1859.9. Omitting MSI status 
made little difference, with AIC values of 2806.9 and 1863.0. Replacing histologic grade 
with the new proposed grading system separating tumors into 2 groups based on the 
combined effect of MSI and histologic grade gave an AIC value of 2803.0 for all-cause 
mortality and 1856.0 for colorectal cancer-specific mortality, representing a better model fit. 
Similarly, for colorectal cancer-specific mortality the Cox model according to the new 
grading system gave the lowest most favorable AIC value. 
 
Discussion 
Our aim was to investigate the combined effect of histologic grade and MSI status on the 
survival of patients diagnosed with colorectal adenocarcinoma. Our finding of improved 
survival associated with MSI in colorectal carcinomas of any histologic subtype is consistent 
with previous reports [11-13]. This supports the recent WHO recommendation to grade 
mucinous carcinoma according to their MSI status [3]. We found that patients with high-
grade adenocarcinoma had significantly lower survival than patients with low-grade 
adenocarcinoma only when the tumor was MSS. Patients with an MSI high-grade tumor had 
similar survival compared with patients with low-grade tumors of MSI or MSS subgroups. 














histologically high-grade colorectal adenocarcinomas should take account of MSI status. The 
high-grade category should be restricted to adenocarcinomas displaying high grade histologic 
features and that are MSS (Table 4). The significant difference in survival between the MSI 
high-grade and the MSS high-grade subgroups suggests that the positive effect of MSI on 
survival is stronger than the negative effect of high histologic grade. However, our results 
should be interpreted with caution due to small numbers of death in the MSI subgroup. 
Conversely, MSI does not seem to have any effect on low-grade tumors, with no significant 
difference in survival between patients with MSI low-grade tumors and patients with MSS 
low-grade tumors, but the proportion of MSI in low-grade tumors is low (6% in this series) 
and studies with larger numbers would be required to identify such an effect.  
 
A grading system incorporating MSI with the traditional histologic grades would potentially 
affect 10-20% of all colorectal carcinomas classified as histologically high-grade 
adenocarcinomas. From this subgroup, 20-50% of tumors are expected to be MSI and would 
then be reclassified as low-grade adenocarcinomas. In this study, the proportion of MSI in 
high-grade adenocarcinomas was 20%, which is low compared with other studies that report 
up to 50% of MSI in high-grade tumors [19]. This difference may be due to the lack of 
standardization to define an adenocarcinoma as histologically high-grade [3, 4, 8, 20]. While 
the WHO clearly sets the cutoff for gland formation to 50% to separate low-grade from high-
grade adenocarcinomas, it is further specified that grading is based upon the least 
differentiated component, with the invading edge of tumor regarded as suboptimal to evaluate 
tumor grade [3]. Unfortunately, the definition of the least differentiated area remains unclear 
and this makes comparisons between series difficult. In our study, adenocarcinomas were 
graded according to the area showing the least differentiated component which had to be 














greater proportion of adenocarcinomas with high grade histologic features (18%) compared 
with studies that assessed the whole analyzed tumor area for histologic grading as 
recommended by the AJCC and the College of American Pathologists (CAP) guidelines. 
When histologically high-grade, MSI adenocarcinomas are often more homogeneous with 
>50% of the tumor showing poor differentiation. It is, therefore, expected that both grading 
systems would include comparable numbers of MSI high-grade adenocarcinomas. 
Heterogeneity is frequently observed in MSI carcinomas but usually by the frequent 
occurrence of minor mucinous carcinoma components in an otherwise low-grade 
adenocarcinoma [14, 21]. The difference in proportions of high-grade adenocarcinomas is 
likely to be explained by the inclusion of tumors with overall <50% gland formation (i.e. 
called low-grade according to the AJCC/CAP system) but with minor areas of poorly 
differentiated adenocarcinoma that were sufficient to call the tumor high-grade histologically, 
as in this study and recommended by the WHO. Focal areas of poor differentiation have been 
referred to as poorly differentiated clusters by some authors and it has been reported to be 
associated with other histologic variables of poor prognosis, such as tumor budding, 
infiltrating tumor front and nodal metastasis [22, 23]. Ueno et al. proposed a histologic 
grading system based on the number of poorly differentiated clusters, which better stratified 
patients by clinical outcome than the traditional grading system based on the proportion of 
gland formation in the tumor [24, 25]. Reporting tumors with these aggressive morphologic 
features as low grade is counterintuitive as is the reporting of poorly differentiated MSI 
tumors as high grade. Most histologically high-grade adenocarcinomas characterized by 
poorly differentiated clusters are likely to be MSS and, therefore, not affected by the 
incorporation of MSI in the final grade. Our results on incorporating MSI to the grading of 
colorectal adenocarcinoma with high grade histologic features need to be verified when 














suggest that the WHO grading system of adenocarcinoma may be more appropriate for 
patient prognostication than the AJCC/CAP system, which may undergrade tumors with a 
focal poorly differentiated component present in <50% of examined tumor, possibly 
secondary to sampling error. We propose that one microscopic field at magnification x40 
away from the invading edge could be used as the minimum area containing poor 
differentiation for a colorectal adenocarcinoma to be classified histologically as a high-grade 
tumor. 
 
In 1986, Jass et al. [9] established a grading system using a Cox regression model based on 
data from 447 resected rectal adenocarcinomas. The variables that best predicted survival 
included tubule configuration (regular, irregular, none), lymphocytic infiltration (marked, 
moderate, little or none) and tumor growth pattern (expanding, infiltrating). The best score (a 
score of 0) was attributed to tumors showing marked lymphocytic infiltration and an 
expanding growth pattern. The Jass grading system was, therefore, heavily influenced by 
these two variables which have been subsequently found to be typical characteristics of MSI 
colorectal adenocarcinoma [26]. That is, our proposed criteria for integrating MSI status with 
the histologic grading of colorectal adenocarcinoma can be seen as a simplified version of the 
Jass grading system. Poor reproducibility of the Jass grading system has been reported by 
some authors [27] and this might have hampered its uptake by pathologists. A growing 
number of pathology laboratories are now implementing upfront MSI testing for all newly 
diagnosed colorectal carcinomas, usually by immunohistochemistry. The reliability of MMR 
immunohistochemistry and its good concordance with molecular methods make MSI status 
an easy and reproducible parameter to be widely used in pathology laboratories [28]. 














samples and resection specimens [29], allowing appropriate grading at time of the initial 
diagnosis from the endoscopic biopsy. 
 
In conclusion, we found that patients with colorectal adenocarcinoma are better stratified by 
survival when the MSI status of the tumor is incorporated in the grading system. Patients with 
high-grade MSI adenocarcinomas had similar survival to patients with low-grade 
adenocarcinomas. We propose that the grading of colorectal adenocarcinoma with high-grade 
histologic features, present in at least one microscopic field at magnification x40, should be 
made according to the MSI status of the tumor. As molecular pathology increasingly 
supplements morphology, pathologists will be able to integrate clinically useful biologic 
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Table 1. Number of colorectal cancer patients (N=738) and deaths by histologic type, 








    All cause, 
N (%) 
Colorectal 
cancer, N (%) 
Adenocarcinoma      
      Low-grade      
MSS 514 (94) 229 (45) 67.8 244 (47) 142 (28) 
MSI 35 (7) 25 (71) 70.8 15 (43) 4 (11) 
      High-grade      
MSS 95 (80) 50 (53) 68.9 75 (79) 67 (71) 
MSI 24 (20) 17 (71) 70.4 13 (54) 5 (21) 
Mucinous carcinoma      
MSS 35 (60) 16 (46) 68.4 16 (46) 11 (31) 
MSI 23 (40) 11 (48) 66.8 5 (22) 2 (9) 
Signet ring cell 
carcinoma 
     
MSS 5 (62) 5 (100) 61.8 5 (100) 4 (80) 
MSI 3 (38) 0 (0) 73.8 2 (67) 1 (33) 
Undifferentiated 
carcinoma (all MSS) 
3 3 (100) 62.6 2 (67) 1 (33) 
Medullary carcinoma 
(MSI) 






























Table 2. Hazard ratios for all-cause and colorectal cancer-specific mortality with no 
adjustment in the subgroup of adenocarcinoma patients. 
Variable All-cause Colorectal cancer 
HR (95% CI) P HR (95% CI) P 
MSI (main effect)  0.88 (0.52-1.49) 0.637 0.39 (0.15-1.06) 0.066 
High-grade (main effect) 3.02 (2.32-3.92) <0.001 4.20 (3.13-5.64) <0.001 
Interaction term 0.43 (0.20-0.95) 0.037 0.45 (0.12-1.74) 0.248 




    
1 (Referent)  1 (Referent)  




    
3.02 (2.32-3.92) <0.001 4.20 (3.13-5.64) <0.001 
1.15 (0.66-2.01) 0.624 0.75 (0.31-1.82) 0.521 
 

















Table 3. Hazard ratios for all-cause and colorectal cancer-specific mortality with adjustment 
for sex, age-group and stratified by AJCC stage in the subgroup of adenocarcinoma patients. 
Variable All-cause Colorectal cancer 
HR (95% CI) P HR (95% CI) P 
Female 0.84 (0.66-1.05) 0.128 0.91 (0.68-1.20) 0.497 
Age-group (years):  
   <60 1 (Referent)  1 (Referent)  
   60-70 1.24 (0.85-1.80) 0.267 1.11 (0.73-1.70) 0.614 
   70+ 1.92 (1.35-2.74) 0.000 1.27 (0.85-1.89) 0.245 
MSI (main effect)  1.10 (0.63-1.92) 0.731 0.62 (0.23-1.71) 0.360 
High-grade (main effect) 2.09 (1.58-2.77) <0.001 2.54 (1.86-3.47) <0.001 
Interaction (MSI and grade) 0.50 (0.22-1.13) 0.097 0.53 (0.14-2.07) 0.364 




    
1 (Referent)  1 (Referent)  




    
2.09 (1.58-2.77) <0.001 2.54 (1.86-3.47) <0.001 
1.15 (0.63-2.07) 0.653 0.85 (0.34-2.08) 0.715 
 
Abbreviations: HR: Hazard ratio; CI: Confidence interval; MSS: Microsatellite stable; MSI: 















Table 4. Proposed new grading criteria for colorectal adenocarcinoma combining histologic 
grade (tumor differentiation) and microsatellite instability (MSI) status (MSI versus 
microsatellite stable (MSS)) 




Histologic grade MSI status New grade 
0-49% Poor High-grade MSS High-grade 
0-49% Poor High-grade MSI Low-grade 
50-100% Moderate or well-
differentiated 
Low-grade MSS Low-grade 
50-100% Moderate or well-
differentiated 
Low-grade MSI Low-grade 
* in at least one microscopic field at magnification x40 
Abbreviations: MSS: Microsatellite stable; MSI: Microsatellite instable  
 
 
















Figure 1. Examples of colorectal adenocarcinoma with high histologic grade and different 
microsatellite instability status. A. Histologically high grade adenocarcinoma associated with 
a microsatellite stable (MSS) phenotype showing only focal gland formations with ‘dirty 
necrosis’ and overall poor differentiation. B. Histologically high grade adenocarcinoma with 
a microsatellite instability (MSI) phenotype showing tumor infiltrating lymphocytes and very 
focal gland formations. 
 
Figure 2. Kaplan-Meier survival curves showing overall survival (A) and colorectal-cancer 
specific survival (B) according to microsatellite status (MSI and MSS) for all histologic 
types. 
 
Figure 3. Kaplan-Meier survival curves showing overall survival (A-C) and colorectal-
cancer specific survival (D-F) according to histologic grade (low-grade versus high-grade) 
and microsatellite status (MSI and MSS) (A and D), histologic grade only (B and E), and the 
new grading system with high-grade MSS vs other (C and F), in colorectal adenocarcinoma 
patients.  
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